

CP380C

PATENT

USSN 10/649,776 filed 8/28/03

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

- 1.(previously presented) A method of treating melanoma in a human, which comprises administering parenterally a therapeutically effective amount of arsenic trioxide to said human.
2. (canceled)
- 3.(previously presented) The method of claim 1, wherein said arsenic trioxide is formulated as an ionic aqueous solution.
- 4.(original) The method of claim 1, wherein the total daily amount administered is from about 10  $\mu$ g to about 200 mg.
- 5.(original) The method of claim 1, wherein the total daily amount administered is from about 0.5 mg to about 150 mg.
- 6.(original) The method of claim 1, wherein the total daily amount administered is from about 0.5 mg to about 70 mg.
- 7.(previously presented) The method of claim 1, wherein the arsenic trioxide is administered intravenously.
- 8.(currently amended) The method of claim 1, wherein the arsenic trioxide is administered in combination with an effective amount of at least one other therapeutic agent.
- 9.(original) The method of claim 8, wherein the other therapeutic agent is a chemotherapeutic or radiotherapeutic.

CP380C

PATENT

USSN 10/649,776 filed 8/28/03

10.(original) The method of claim 8, wherein the other therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26(vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.

11. (canceled)